ストックスクリーナーアプリを入手
4.47
1.54%
-0.07
Relay Therapeutics Inc (RLAY) 最新ニュース
Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells $166,846.68 in Stock - MarketBeat
Peter Rahmer Sells 17,250 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock - MarketBeat
Relay Therapeutics Insider Sold Shares Worth $268,339, According to a Recent SEC Filing - Marketscreener.com
Relay Therapeutics Inc (RLAY) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Relay Therapeutics CEO Sanjiv Patel sells $1.76 million in stock - MSN
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down on Insider Selling - Defense World
Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells $600,000.00 in Stock - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Down 6%Here's What Happened - MarketBeat
Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price Target - MSN
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down After Insider Selling - MarketBeat
Relay Therapeutics CEO Sanjiv Patel sells $1.76 million in stock By Investing.com - Investing.com UK
Relay Therapeutics (NASDAQ:RLAY) Trading 6.8% HigherHere's Why - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week LowShould You Sell? - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest Update - MarketBeat
Relay Therapeutics' SWOT analysis: stock poised for growth amid fierce competition - MSN
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8%Time to Sell? - MarketBeat
We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate - Yahoo Finance
Relay Therapeutics’ (RLAY) Buy Rating Reiterated at HC Wainwright - Defense World
Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week LowShould You Sell? - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Given "Buy" Rating at HC Wainwright - MarketBeat
Relay Therapeutics Highlights Progress at Healthcare Conference - TipRanks
Barclays PLC Grows Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Barclays PLC Purchases 136,541 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws - MSN
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Relay Therapeutics stock hits 52-week low at $4 By Investing.com - Investing.com South Africa
Relay Therapeutics (NASDAQ:RLAY) Hits New 12-Month LowShould You Sell? - MarketBeat
Relay Therapeutics stock hits 52-week low at $4 - Investing.com India
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws (LLY:NYSE) - Seeking Alpha
Relay Therapeutics Chief Corporate Development Officer Peter Rahmer Sells 63% Of Holding - Simply Wall St
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 4.8%Should You Buy? - MarketBeat
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Relay Therapeutics officer sells shares worth $345,571 By Investing.com - Investing.com Australia
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells $73,763.20 in Stock - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 32,156 Shares - MarketBeat
Relay Therapeutics officer sells shares worth $345,571 - Investing.com India
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by JPMorgan Chase & Co. - Defense World
3.95%
2.39%
大文字化:
|
ボリューム (24 時間):